UBS Group Initiates Coverage on Ascendis Pharma A/S (NASDAQ:ASND)

Research analysts at UBS Group started coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $196.00 price target on the biotechnology company’s stock. UBS Group’s price target would suggest a potential upside of 39.72% from the stock’s current price.

Several other research analysts also recently issued reports on ASND. Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Bank of America increased their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Wells Fargo & Company boosted their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Stifel Nicolaus lifted their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, TD Cowen cut their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $192.07.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $140.28 on Tuesday. The stock has a market cap of $8.51 billion, a PE ratio of -17.36 and a beta of 0.65. The business has a fifty day moving average of $131.85 and a two-hundred day moving average of $133.52. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds have recently modified their holdings of the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth about $30,000. GAMMA Investing LLC raised its position in shares of Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 214 shares during the period. Signaturefd LLC raised its position in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the period. Pursue Wealth Partners LLC bought a new position in shares of Ascendis Pharma A/S during the third quarter worth about $217,000. Finally, Rhumbline Advisers grew its holdings in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.